Literature DB >> 10069663

Overexpression of fibroblast growth factor receptor 3 in a human thyroid carcinoma cell line results in overgrowth of the confluent cultures.

H Onose1, N Emoto, H Sugihara, K Shimizu, I Wakabayashi.   

Abstract

Recent reports indicate that a gain-of-function mutation in fibroblast growth factor receptor 3 (FGFR-3) inhibits cell growth in the cartilaginous growth plates. These results suggest that FGFR-3 may be the receptor transducing growth inhibitory signals. Using reverse transcription-PCR we examined seven papillary thyroid carcinomas to determine FGFR-3 expression. Six out of the seven papillary carcinomas expressed FGFR-3. To clarify the role of FGFR-3 in thyroid carcinoma, FGFR-3 was overexpressed in an established human papillary thyroid carcinoma cell line. High levels of FGFR-3 protein were identified in cells stably transfected with the vector containing FGFR-3 cDNA. The specific binding of 125I-FGF-2 of these cells was threefold higher than that of control cells. Growth rates of cells overexpressing FGFR-3 were similar to those of control cells. However, cells overexpressing FGFR-3 continued to grow beyond the density at which control cells stopped proliferating. These results suggest that FGFR-3 in thyroid carcinoma is not involved strongly in the cell proliferation mechanism but may contribute to the malignant extension of some of the carcinomas by modifying cell contact signaling.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10069663     DOI: 10.1530/eje.0.1400169

Source DB:  PubMed          Journal:  Eur J Endocrinol        ISSN: 0804-4643            Impact factor:   6.664


  4 in total

1.  FGF9/FGFR2 increase cell proliferation by activating ERK1/2, Rb/E2F1, and cell cycle pathways in mouse Leydig tumor cells.

Authors:  Ming-Min Chang; Meng-Shao Lai; Siou-Ying Hong; Bo-Syong Pan; Hsin Huang; Shang-Hsun Yang; Chia-Ching Wu; H Sunny Sun; Jih-Ing Chuang; Chia-Yih Wang; Bu-Miin Huang
Journal:  Cancer Sci       Date:  2018-10-23       Impact factor: 6.716

Review 2.  Spotlight on lenvatinib in the treatment of thyroid cancer: patient selection and perspectives.

Authors:  Ricardo Costa; Benedito A Carneiro; Sunandana Chandra; Sachin G Pai; Young Kwang Chae; Jason B Kaplan; Hannah B Garrett; Mark Agulnik; Peter A Kopp; Francis J Giles
Journal:  Drug Des Devel Ther       Date:  2016-02-29       Impact factor: 4.162

3.  Tumour formation by single fibroblast growth factor receptor 3-positive rhabdomyosarcoma-initiating cells.

Authors:  M Hirotsu; T Setoguchi; Y Matsunoshita; H Sasaki; H Nagao; H Gao; K Sugimura; S Komiya
Journal:  Br J Cancer       Date:  2009-11-03       Impact factor: 7.640

4.  Fibroblast growth factor receptor-2 expression in thyroid tumor progression: potential diagnostic application.

Authors:  Adriano Redler; Giorgio Di Rocco; Domenico Giannotti; Francesca Frezzotti; Maria Giulia Bernieri; Simona Ceccarelli; Sirio D'Amici; Enrica Vescarelli; Anna Paola Mitterhofer; Antonio Angeloni; Cinzia Marchese
Journal:  PLoS One       Date:  2013-08-19       Impact factor: 3.240

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.